WASHINGTON, Dec. 2, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported results in a Phase II clinical study of VQW-765, a novel small molecule alpha 7 nicotinic acetylcholine receptor (α7-nAChR) partial agonist, in the treatment of acute performance anxiety in social situations, such as public speaking.

In clinical study VP-VQW-765-2201 (Study 2201), 230 volunteers with prior history of performance anxiety were randomized to receive a single dose of VQW-765 or placebo and were challenged with the standardized Trier Social Stress Test (TSST). The TSST creates an acute stress by requiring participants to make an interview-style presentation in front of a panel who provides no feedback or encouragement. Participants who received VQW-765 showed numerically lower stress levels compared to those who received placebo.

3D Model of ATP Synthase - molecular motor (enzyme) that powers cells, generating chemical energy in the form of ATP molecules.

The 1997 Nobel prize in Chemistry was awarded to John Walker and Paul Boyer for solving the structure and mechanism of the enzyme ATP synthase which is involved in the synthesis of adenosine triphosphate (ATP). ATP is a molecule that provides energy to drive many processes in living cells.

Join Venable’s Ari J. Markenson, Ilisa Halpern Paul, and Joshua Raymond in a discussion of the implications for national healthcare and life sciences policy following the results of the midterm congressional election.  Ari will moderate the discussion with Ilisa and Joshua as they provide insights into and analysis of what investors, lenders, providers, manufacturers, and stakeholders might expect in the next 18 to 24 months with respect to federal health policy. The discussion will cover a wide range of topics, such as the anticipated House and Senate policy agendas, regulatory priorities for the Biden-Harris administration, and potential areas of bipartisan agreement. There will be time for questions from the audience following the panel.

Maryland Manufacturing Extension Partnership joins City/County consortium to expand third Biotech Bootcamp in Frederick

FREDERICK, MD. (PRWEB) DECEMBER 01, 2022

Following the completion of two successful sessions, Frederick Community College, Frederick County Workforce Services, The City of Frederick Department of Economic Development, and the Frederick County Office of Economic Development are pleased to announce the next "Biotech Bootcamp" will be held in Frederick in January 2023. Maryland Manufacturing Extension Partnership (Maryland MEP) has joined the Frederick consortium to provide additional programming support aimed at expanding the program’s footprint in the future.

A year marked mostly by biopharma mergers and acquisitions (M&A) in the hundreds of millions of dollars could end with a blockbuster, depending how far Horizon Therapeutics (HZNP) gets, and how quickly its talks with a trio of potential suitors, all of them being corporate giants.

Horizon shares jumped 27% from $78.76 to $100.29 on Wednesday, the first trading day after the company announced that it was in M&A talks with Amgen (AMGN), Johnson & Johnson (JNJ)’s Janssen Global Services, and Sanofi (SAN, SNY), confirming a report in The Wall Street Journal.

Over the past four fiscal years, there have been 1,977 initial public offerings (IPOs) completed by companies headquartered in the U.S., according to PitchBook, yielding more than $549 billion in capital invested. These companies are located in 45 states, D.C., and Puerto Rico. Almost 20% of those companies are no longer publicly held, having been returned to private ownership, been acquired, merged or gone out of business.

Across the four years, data shows a spike of IPO size and count in 2021, with a total IPO count of 956 and total IPO size of $315.7 billion for the year.

Image: https://ssti.org

After creating the satellite-radio industry and developing a drug for her daughter's serious disease, Martine Rothblatt is leading her biotech to test another boundary of what's possible.

The 68-year-old entrepreneur's newest mission is to create an endless supply of organs. Her company, the $12 billion Maryland-based biotech United Therapeutics, has already put gene-edited pig hearts, lungs, and kidneys into humans in clinical studies. Rothblatt now hopes to start making organs with 3D printing to solve the organ-supply crisis, with over 100,000 Americans on waiting lists for transplants.

Image: Martine Rothblatt, CEO of United Therapeutics, previously founded the satellite-radio pioneer SiriusXM. Elijah Nouvelage/REUTERS

Cancer continues to be a leading cause of mortality worldwide, accounting for nearly 10 million deaths in 2020. Alongside growing incidence rates each year, knowledge of molecular and tumor biology has also increased and notably affected cancer treatment paradigms. Until recently, cancer therapeutics focused on four main types of treatment: surgery, chemotherapy, radiotherapy, and targeted therapy. However, over the past ten years, immunotherapy has emerged as a novel and revolutionary approach to cancer treatment.

There is a new revolution of technology emerging based on the understanding of sub-atomic physics: quantum. This revolution leverages advanced scientific understanding and engineering capabilities at the sub-atomic level to create new solutions across critical domains such as computing, sensing, cryptography, materials, and communications. Through particle-level precision controls, technologies may provide uniquely powerful, fast, and precise capabilities that will benefit society.

You’ve Created the Technology. Put It to Work with I-Corps.

I-Corps at NIH is an entrepreneurship training program specifically designed for companies that received Small Business Innovation Research or Small Business Technology Transfer funding from NIH and the Centers for Disease Control and Prevention (CDC). During this 8-week, hands-on program, you’ll learn how to focus your business plan and get the tools to bring your treatment to the patients who need it most.

I-Corps Program Benefits

• Get funding up to $55,000 to cover program costs.
• Receive training from biotech sector experts.
• Expand your professional network.
• Build the confidence and skills to create a comprehensive business model.
• Gain years of entrepreneurial skills in only weeks.

Questions about the program should be directed to the agency contact at your awarding NIH/CDC institute or to one of the contacts in the table below.

Expedited Bill 31-22 will alter eligibility requirements of the Small Business Innovation Research and Small Business Technology Transfer Matching Grant Program

ROCKVILLE, Md., Nov. 29, 2022—Today the Montgomery County Council unanimously passed legislation that will fuel economic development by providing the County Executive with greater flexibility regarding the administration of the County's program to match federal Small Business Innovation Research and Small Business Technology Transfer grants. The legislation is sponsored by Planning, Housing and Economic Development (PHED) Committee Chair Hans Riemer and Councilmembers Will Jawando and Andrew Friedson, who sit on the PHED Committee.

Illumina Accelerator alum Polaris Genomics is investigating how genomics can help diagnose post-traumatic stress disorder (PTSD) and other mental health issues. The Maryland-based company is developing genomic panels that could more objectively screen people for PTSD and help them get the care they need.

“Our mission is to make these invisible wounds visible using the power of genomics,” says Polaris Co-Founder and CEO Charles Cathlin. “We believe genomics is a driving force to connect mental illness to its biological underpinnings. By doing that, we can decrease the stigma, suffering, silence, and suicide.”

Image: Polaris Chief Medical Officer Dr. Anne Naclerio and Polaris Co-Founder and CEO Charles Cathlin | Photo: Noah Willman

SANTA MONICA, Calif. & AMSTERDAM--(BUSINESS WIRE)--Neogene Therapeutics, Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts), today announced it has entered into a definitive agreement to be acquired by AstraZeneca.

With a shared goal of bringing cell therapies to patients with solid tumors, Neogene’s expertise in TCR-T discovery, development and manufacturing will strengthen AstraZeneca’s ambition to transform outcomes for patients.

The NIH Technology Transfer Program has won the Licensing Executive Society’s Deals of Distinction award for 2022. The Deals of Distinction Award is given to an outstanding licensing deal from the past year. Steve Ferguson, Special Advisor at the NIH Office of Technology Transfer, recently attended the LES award ceremony to accept the award on NIH’s behalf. Continue reading to learn about this award-winning license agreement from Steve himself.

For this LES “Deals of Distinction” Award the National Institutes of Health (NIH) licensed COVID-19 technologies arising from our intramural research to the Medicines Patent Pool (MPP) for access through the World Health Organization’s (WHO) COVID-19 Technology Access Pool (C-TAP). These licenses for COVID-19 technologies will enable global manufacturers to develop COVID-19 vaccines, treatments, and diagnostics for low- and middle-income countries (LMICs), where access to COVID-19 countermeasures is severely lacking.

Updated 11/29

BioHealth Innovation, Inc. (BHI) and Montgomery County are pleased to announce the selection of Luis Gutierrez as a part-time “Executive in Residence”—a position dedicated to providing 1:1 technical assistance to Montgomery County-based biotech and medtech startups.

We’re excited to announce this year’s finalists for the third annual 2022 BioBuzz Awards. These awards celebrate the people and companies across our regional community and their efforts and accomplishments to impact human health and build a stronger biotech community.

The annual BioBuzz awards celebrate the people, companies and communities across the BioHealth Capital Region and, starting this year, Greater Philadelphia. These awards laud and recognize their efforts and to impact human health and build stronger, more vibrant biotech communities.

There are so many people and organizations doing great work in these regions, selecting finalists was not an easy task. We’re very excited to announce this year’s BioBuzz Awards finalists for 2022.

Johns Hopkins Medicine researchers have revamped an anti-cancer drug to better target cancer cells and leave healthy tissues unharmed. Scientists have dubbed this type of targeted approach a “prodrug” — a medicine designed to release its payload in a particular area of the body and in no other areas. The Johns Hopkins-discovered prodrug, called DRP-104 (sirpiglenastat), is in early-stage clinical trials in people with advanced solid tumors. The newly published studies in mice show that the augmented drug preferentially eliminates cancer cells but does not harm healthy cells.

Biotechnology firm Haystack Oncology Inc. has signed a lease in the City Garage Science & Technology Center at the recently rebranded Baltimore Peninsula mixed-use development.

Haystack, which describes itself as developing personalized cancer diagnostics with the potential of leading to proactive clinical interventions, said it's moving into a 20K SF lab space in City Garage at 101 West Dickman St. by this coming summer.

Image: Google Maps - City Garage in south Baltimore is a former makers' hub turned life sciences laboratory space.

HILDEN, Germany & GERMANTOWN, Maryland--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the monkeypox (MPXV) test for its NeuMoDx automated PCR platform to strengthen surveillance and research into the current outbreak in non-endemic regions that has infected tens of thousands of people all over the world since first being identified in May 2022.

“NeuMoDx MPXV enables researchers the fast and reliable qualitative detection and differentiation of both monkeypox clades, a huge help for those trying to understand and contain this virus”

ROCKVILLE, MD, Nov. 17, 2022 (GLOBE NEWSWIRE) --

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that the U.S. Food and Drug Administration announced the approval of the Biologics License Application (BLA) for teplizumab, an anti-CD3 monoclonal antibody that was previously developed by MacroGenics.  Teplizumab was acquired by Provention Bio, Inc. in May 2018 pursuant to an asset purchase agreement.

"We are very pleased to see the culmination of years of effort by Provention, MacroGenics, and tireless champions in academia and government, with the achievement of the approval of teplizumab," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. "We applaud this outcome, which represents an advancement for individuals and their families dealing with the risks and consequences of type 1 diabetes."

In Montgomery County, lab space has long been a prized get for biotechs, because there was so little of it. Shockingly little, actually, given the county is home to both the National Institutes of Health and the Food and Drug Administration.

That’s changing, and fast. There’s about 2 million square feet of the specialized space in the county’s pipeline, much of it taking the place of obsolete office buildings that are either being converted to labs, or demolished in favor of gleaming, state-of-the-art new construction.

NEW YORK, Nov. 15, 2022 /PRNewswire/ -- The Princeton Review® and Entrepreneur® today announced the results of The Princeton Review's 17th annual ranking of undergraduate and graduate schools for entrepreneurship studies.

Based on a summer 2022 survey The Princeton Review conducted of nearly 300 schools with entrepreneurship offerings, the rankings reported today took into account more than 40 data points about the school programs, faculties, students, and alumni.

The Princeton Review and Entrepreneur published the project's ranking lists on their respective websites at https://www.princetonreview.com/entrepreneur and https://www.entrepreneur.com/topcolleges.

Pixelligent, a nanotechnology firm that produces materials used in augmented reality displays and sensors, recently raised $38 million in IP-backed financing from a funding vehicle by MVolution Partners LLC. These funds brings the total raised this round of funding to $45 million, with the other $7 million coming from existing investors.

Image: Inside Pixelligent's manufacturing facility. (Courtesy photo)

According to a recent report from CBRE, Chicago ranks No. 6 for job growth out of the Top 25 life sciences markets in the U.S. To establish itself as a prominent hub on par with the coastal life sciences clusters in Boston and San Francisco, Chicago needs to enhance its offering in the areas of funding, talent, real estate and infrastructure. While the city has made many positive strides toward becoming a life sciences destination, there are four key steps city and state leaders can take to accelerate this process.

Image: https://www.pexels.com/photo/architectural-photography-of-tunnel-2088233/

Apply Now for Our 2023 Programs!

Applications for our three different Innovator programs – MedTech Innovator US, MedTech Innovator Asia Pacific, and BioTools Innovator – are now open. Read below to learn which program is right for you and apply today.

Companies do not have to relocate, and there is no equity required or fee for participation. The application deadline for all programs is January 31, 2023.

Image: https://thelaunchport.com

Emergent BioSolutions is looking to make progress with its chikungunya vaccine and has received a $10 million US government grant to help it along.

Emergent announced that it has been handed a research award from the Department of Defense Congressional Directed Medical Research Programs to evaluate the efficacy of its single-dose chikungunya virus vaccine candidate.

The coronavirus pandemic has underlined the value of clearly communicating scientific data, public health guidance and risk factors amidst uncertainty. On Tuesday, Dec. 6 at 9:00 a.m. ET, join Washington Post Live for a series of conversations with Francis S. Collins, former director of the National Institutes of Health, Katrine Wallace, an epidemiologist from the University of Illinois Chicago School of Public Health, and Kurt Newman, president and CEO of Children’s National Hospital, about strengthening trust in science across society, countering misinformation and navigating heightened political divisions.

Image: https://www.washingtonpost.com/

October 6, 2022 – Now accepting Letters of Intent (LOI) for Grant Round 14 

Dec 7, 2022   5:00 PM EDT  Deadline to submit LOI for consideration in Grant Round 14

December 16, 2022   Invitation to submit a full application will be sent to Applicant Teams whose LOI meets funding criteria

February 2, 2023  5:00 PM Eastern  Deadline to submit full application for Grant Round 14

February 24, 2023  Invitation to present proposal in person to our Project Management and Oversight Panel (PMOP) will be sent to the top 8 applicant teams as determined by scoring and ranking of applications

Week of March 13, 2023  Proposal Presentations 

Week of March 20, 2023 Virginia Board of Directors final funding decision for Grant Round 14 March 2023  Grant Round 14 Awardees announced

Hello everybody, Wizbiosolutions team is MEDICA in Dusseldorf. We are in Hall 1, E18 now. Please come to visit our booth and discuss about new technology that we have. We are all welcomeing you.

Image: https://www.linkedin.com

The Johns Hopkins University researchers behind two of Baltimore's most successful biotech firms have founded a new company that has now raised $56 million to create a new diagnostic tool for cancer.

Haystack Oncology plans to use the funding from its series A round to kickstart a move into a large lab inside of City Garage in Port Covington, which was recently renamed Baltimore Peninsula. The company also plans to invest in more clinical trials to get additional data to support the effectiveness of Haystack's cancer detection blood test. The 50-person company, currently based at Hopkins' FastForwardU, plans to have a commercial launch in 2023.

From New York to Paris and London, life sciences companies are being drawn to parts of town often more synonymous with financial services. In London, the Canary Wharf Group and Kadans Science Partner are jointly developing Europe’s largest commercial laboratory building. Life science organization Genomics England will move in later this year, joined by a mix of startups, academics, clinicians and established pharmaceutical companies.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, invests more than € 290 million in its biosafety testing capacity at Rockville, Maryland, USA. This will significantly increase the company’s ability to conduct biosafety testing and analytical development services. Biosafety testing and analytical development are critical and fundamental requirements of the drug development and commercialization process to ensure the safety of medicines. Global demand for these services is growing at a double-digit rate.

A few of BioBuzz’s favorite stories from late summer/early fall Over the past several months, life sciences companies across the BioHealth Capital Region showcased their innovative capabilities and pipeline development program. BioBuzz takes a look back at five key events that took place in the third quarter.

BioFactura Moves Forward with Stelara Biosimilar

Frederick, Maryland-based BioFactura is beginning to see the fruits of its labors with the development of ustekinumab (BFI-751), its biosimilar for Janssen’s Stelara. In October, the company announced Phase 1 data that showed pharmacokinetic comparability to the comparison drug.

The company also reported there were no marked differences in the safety and tolerability profile for subjects receiving ustekinumab. BioFactura intends to conduct a confirmatory safety and efficacy study in patients to pave the way for global registration.

Image: https://biobuzz.io/

BALTIMORE, MD (November 16, 2022) — Governor Larry Hogan today announced that MilliporeSigma, an international biosciences company, is growing its presence in Montgomery County with a $286 million investment to expand its biosafety testing capacity.

The company, known locally as BioReliance Corporation, currently has five locations in Rockville and is planning to consolidate in a new 250,000-square-foot facility at 9820 Darnestown Road at the Alexandria Center® at Traville Gateway campus, which is being developed and operated by Alexandria Real Estate Equities, Inc. MilliporeSigma will maintain one additional facility at 9630 Medical Center Drive and will retain at least 600 full-time employees during the expansion, while creating more than 500 new jobs over the next four years.

BELTSVILLE, Md. and DAEJEON, South Korea, Nov. 15, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC) and LegoChem Biosciences, Inc. (LCB, KOSDAQ: 141080) today announced a collaboration and co-development agreement focused on generating a B7-H4 antibody drug conjugate (ADC) and options for two additional targets. The B7-H4 ADC will utilize NextCure’s B7-H4 antibody and LCB’s ConjuAllTM ADC technology.

Under the terms of the agreement, both parties will equally share the costs to develop the molecules and profits on commercialized products. The parties will utilize their respective product development capabilities to generate the B7-H4 ADC and advance it to the clinic. In addition, there are options for the parties to nominate two additional targets for ADC development beyond B7-H4.